Skip to content

Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis

A Study to Understand the Treatment Patterns in Patients With Chronic Bacterial Prostatitis (Category II), Chronic Pelvic Pain (Category IIIA, IIIB)Treataprost Added to Standard Antibiotic Treatment in Real-life Clinical Practice

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05306314
Acronym
Treataprost
Enrollment
140
Registered
2022-04-01
Start date
2022-04-15
Completion date
2023-10-15
Last updated
2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Bacterial, Prostatitis, PSA, Quality of Life

Brief summary

Multicenter, Retrospectivecohort study in patients with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) and 140 patients without other significant comorbidities will be participated. The aim of the study is to collect post-treatment data to evaluate inflammation, infection status and quality of life with standard antibiotic therapy with NSAID and added Treataprost effect.

Detailed description

This study will be conducted in Patients with Confirmed Chronic Prostatitis and the datas of these patients will be recorded. In real clinical practice, the data of patients who received Treataprost in addition to antibiotic therapy with NSAIDs will be recorded. This is a non-invasive retrospective cohort study. The primary endpoint of this study is: * To determine the socio-demographic (age, educational status, lifestyle) characteristics of cases with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) * Treataprost added to standard antibiotic therapy and NSAID in clinical practice, Chronic Prostatitis, Chronic in patients with Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) understanding treatment patterns The secondary endpoint of this study is: * The aim of the study will to evaluated gather detailed information about the effect on quality of life of Treataprost given with standard antibiotic therapy and NSAID. * It will be collected gather detailed information the infection status after post treatment Treataprost given with standard antibiotic therapy and NSAID

Interventions

DIETARY_SUPPLEMENTTREATAPROST

oral administration before meals 30 minutes

Sponsors

Gama CRO Tıbbi İlaç Araştırma Org.Tic.Ltd.Şti
CollaboratorUNKNOWN
GMG Grand Medical
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patients must be ≥ 18 years old and male. * The participant must be willing and competent to give written informed consent. If the subject is unable to consent on his behalf, a legally acceptable representative (ie, acceptable to the International Council for Harmonization \[ICH\] and local law as appropriate) must give informed consent on his behalf. * Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) diagnosed with standard antibiotic therapy with NSAID and antibiotic therapy with NSAID together with Treataprost patients

Exclusion criteria

* In patients with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) not receiving any treatment * For Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) taking an herbal preparation other than Treataprost in addition to standard antibiotic therapy and NSAID * Patients who have participated in any clinical trial and received an investigational product * Patients who did not give written informed consent

Design outcomes

Primary

MeasureTime frameDescription
To determine the socio-demographic (age, educational status, lifestyle) characteristics of cases with Chronic Prostatitis, Chronic Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB)onceDetermining the relationship between the disease and collecting socio-demographic information such as age, education level, lifestyle
Treataprost added to standard antibiotic therapy and NSAID in clinical practice, Chronic Prostatitis, Chronic in patients with Bacterial Prostatitis (Category II) and Chronic Pelvic Pain Syndrome (Category IIIA, IIIB) understanding treatment patternsonceCollecting data on Treataprost treatment added to standard antibiotic treatment and NSAID in clinical practice

Secondary

MeasureTime frameDescription
The aim of the study will to evaluated gather detailed information about the effect on quality of life of Treataprost given with standard antibiotic therapy and NSAID.OnceTo collect gather detailed information qualirt of life after post treatment
• It will be collected gather detailed information the infection status after post treatment Treataprost given with standard antibiotic therapy and NSAIDonceTo collect gather detailed information the infection status after post treatment

Countries

Turkey (Türkiye)

Contacts

Primary ContactTuba Gun
t.gun@gmgroup.ch+905458101108

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026